Form 4 for VRCA Verrica Pharmaceuticals Inc.
Accepted 2024-11-26 00:00:00 ET · period of report 2024-11-22 · accession 0001415889-24-027709 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-11-26 | 2024-11-22 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | — | +4.49M | 5.98M | +303% | — |
| D | 2024-11-26 | 2024-11-22 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | — | +18.43M | 26.28M | +235% | — |
| D | 2024-11-26 | 2024-11-26 | VRCA | Manning Paul B | Dir, 10% | G - Gift | $0.00 | -450.0K | 25.83M | -2% | $0 |
| DMI | 2024-11-26 | 2024-11-22 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | — | +4.49M | 2.25M | New | — |
| DM | 2024-11-26 | 2024-11-22 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | — | +18.43M | 9.21M | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-22 | P | A | 4,494,382 | — | 5,976,101 | I See footnote | — | — | (F3) The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock. (F4) The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. |
| 2 | Common | Common Stock | 2024-11-22 | P | A | 18,426,966 | — | 26,278,094 | D | — | — | (F1) The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. (F2) The shares are held by Mr. Manning jointly with his spouse. |
| 3 | Common | Common Stock | 2024-11-26 | G | D | 450,000 | $0.00 | 25,828,094 | D | — | — | (F2) The shares are held by Mr. Manning jointly with his spouse. |
| 4 | Derivative | Series A Warrants (right to buy) | 2024-11-22 | P | A | 2,247,191 | — | 2,247,191 | I See footnote | $1.07 · 2024-11-22 to 2025-11-22 | 2,247,191 Common Stock | (F3) The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock. (F4) The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. |
| 5 | Derivative | Series B Warrants (right to buy) | 2024-11-22 | P | A | 2,247,191 | — | 2,247,191 | I See footnote | $1.34 · 2024-11-22 to 2029-11-22 | 2,247,191 Common Stock | (F3) The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock. (F4) The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. |
| 6 | Derivative | Series A Warrants (right to buy) | 2024-11-22 | P | A | 9,213,483 | — | 9,213,483 | D | $1.07 · 2024-11-22 to 2025-11-22 | 9,213,483 Common Stock | (F1) The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. (F2) The shares are held by Mr. Manning jointly with his spouse. |
| 7 | Derivative | Series B Warrants (right to buy) | 2024-11-22 | P | A | 9,213,483 | — | 9,213,483 | D | $1.34 · 2024-11-22 to 2029-11-22 | 9,213,483 Common Stock | (F1) The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. (F2) The shares are held by Mr. Manning jointly with his spouse. |